Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.

Allaire, Manon; Avila, Matias A

Allaire, Manon; Avila, Matias A.

Affiliation

Allaire M; Service d'Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.
Avila MA; INSERM UMR 1138, Centre de recherche des Cordeliers, Paris, France.

Liver Int ; 44(6): 1276-1277, 2024 Jun.

Article in En | MEDLINE | ID: mdl-38775365

Subject(s)

Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Liver Neoplasms; Nutritional Status; Humans; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use; Bevacizumab/therapeutic use; Bevacizumab/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Male; Treatment Outcome; Female; Middle Aged

Key words

atezolizumabbevacizumab; body mass index; hepatocellular carcinoma; nutritional programme

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nutritional Status / Carcinoma, Hepatocellular / Antibodies, Monoclonal, Humanized / Bevacizumab / Liver Neoplasms Limits: Female / Humans / Male / Middle aged Language: En Journal: Liver Int Journal subject: GASTROENTEROLOGIA Year: 2024 Document type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google